-+ 0.00%
-+ 0.00%
-+ 0.00%

RGENTA THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA AND ALIGNMENT ON PHASE 3 TRIAL DESIGN FOR RGT-61159 IN PATIENTS WITH ADENOID CYSTIC CARCINOMA (ACC)

Reuters·10/22/2026 12:03:04